Dr. Chris Boshoff

“I will now provide additional color on the past quarter. Starting with the recent phase three readout for Litfulo in non-segmental vitiligo, a condition affecting more than a million adults in the U.S. alone.”

“It's obviously a very important programme. We're excited with the progress, and since the close of Medsera, as you know, we had exceptional execution, not only in the clinical development, but also on the commercial development side, as well as CMC and on the pharmaceutical sciences as well as the devices.”